• English
  • 简体中文
Login Register
Current Location: Home > Marketing Drugs(EU) Feedback Help Print
Product No EMEA/H/C/004163
Brand Name Cabometyx
Nonproprietary Name cabozantinib
API cabozantinib (s)-malate
ATC Code L01EX07
Indications Renal Cell Carcinoma (RCC)Cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (RCC):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.Cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.Hepatocellular Carcinoma (HCC)Cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.
Orphan Drug no
Generics no
Marketing Authorization Holder Ipsen Pharma
Status Authorised(授权)
Authorization Date 2016-09-09
Version 16
Condition Approval no
Exceptions no
Biosimilar no
Details 查看 (公众评估报告、授权细节、产品规格/剂型、标签、历史评估信息)